Completed PHASE4 INTERVENTIONAL 2-arm NCT01933698

Bioequivalence of Two Commercial Amoxicillin Suspensions

Bioequivalence Study of Two Commercial Amoxicillin Suspension Formulations in Healthy Human Volunteers

Sponsor: Stiefel, a GSK Company

Conditions Bioequivalence of Amoxicillin

Interventions amoxicillin

Updated 5 times since 2017 Last updated: Aug 28, 2013 Started: Feb 28, 2005 Primary completion: May 31, 2005 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Bioequivalence of Amoxicillin and is currently completed. Stiefel, a GSK Company leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stiefel, a GSK Company
University of Campinas, Brazil

Data source: University of Campinas, Brazil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Piracicaba, Brazil